<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

SNS 032 - BMS 387032

產(chǎn)品貨號(hào)

Axon 1614 CAS [345627-80-7] MF C17H24N4O2S2MW 380.53 Purity: 99% Soluble in DMSO Description Specific and potent inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9 (IC50 values to be 38, 4 and 62 nM for cdk2, cdk7 and cdk9 respectively and no activity against 190 additional kinases); SNS 032 induces cell cycle arrest and apoptosis in tumor cell lines References Certificates Categories Extra info DS Williamson et al. Structure-guided design of pyrazolo[1,5-a]pyrimidines as inhibitors of human cyclin-dependent kinase 2. Bioorg. Med. Chem. Lett. 2005, 15(4), 863-867. ? R Chen et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood, 2009, 113(19), 4637-4645.? ? WG Tong et al. Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma. J. Clin. Oncol. 2010, 28(18), 3015-3022.? ? MA Dickson and GK?Schwartz. Development of cell-cycle inhibitors for cancer therapy. Curr. Oncol. 2009, 16(2), 36-43.? Certificate of Analysis Material Safety Data Sheet Apoptosis Cell Cycle Regulation Cell Signaling & Oncology p53-Tumor Suppression EC 2.7.11.22 CDK CDK inhibitor (2, 7 and 9 specific) Chemical name N-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl)piperidine-4-carboxamide Parent CAS No. [345627-80-7] Order Size Unit Price Stock 5 mg €85.00 In Stock

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

SNS 032 - BMS 387032

Based on 8 reference(s) in Google Scholar 9 10 8

Axon 1614

CAS [345627-80-7]

MF C17H24N4O2S2
MW 380.53

Purity: 99%
Soluble in DMSO

SNS 032

Description

Specific and potent inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9 (IC50 values to be 38, 4 and 62 nM for cdk2, cdk7 and cdk9 respectively and no activity against 190 additional kinases); SNS 032 induces cell cycle arrest and apoptosis in tumor cell lines

DS Williamson et al. Structure-guided design of pyrazolo[1,5-a]pyrimidines as inhibitors of human cyclin-dependent kinase 2. Bioorg. Med. Chem. Lett. 2005, 15(4), 863-867.

R Chen et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood, 2009, 113(19), 4637-4645.?

WG Tong et al. Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma. J. Clin. Oncol. 2010, 28(18), 3015-3022.?

MA Dickson and GK?Schwartz. Development of cell-cycle inhibitors for cancer therapy. Curr. Oncol. 2009, 16(2), 36-43.?

Certificate of Analysis
Material Safety Data Sheet

Apoptosis Cell Cycle Regulation Cell Signaling & Oncology p53-Tumor Suppression EC 2.7.11.22 CDK

CDK inhibitor (2, 7 and 9 specific)

Chemical name

N-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl)piperidine-4-carboxamide

Parent CAS No.

[345627-80-7]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>